EDSA logo

Edesa Biotech (EDSA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

21 June 2010

Indexes:

Not included

Description:

EDSA Biotech focuses on developing innovative therapies for serious diseases. The company uses advanced technology to create treatments that target specific health issues. Their goal is to improve patient outcomes and contribute to the future of medicine through research and development in biotechnology.

Events Calendar

Earnings

Next earnings date:

Dec 16, 2024

Recent quarterly earnings:

Aug 09, 2024

Recent annual earnings:

Dec 16, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 11, 2023

Analyst ratings

Recent major analysts updates

29 Nov '23 HC Wainwright & Co.
Buy
22 Nov '23 HC Wainwright & Co.
Buy
12 Oct '23 Brookline Capital
Buy
15 Aug '23 HC Wainwright & Co.
Buy
24 May '23 HC Wainwright & Co.
Buy
15 Mar '23 HC Wainwright & Co.
Buy
14 Feb '23 HC Wainwright & Co.
Buy
20 Dec '21 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Edesa Biotech's Founder Makes Strategic Investment in the Company
Edesa Biotech's Founder Makes Strategic Investment in the Company
Edesa Biotech's Founder Makes Strategic Investment in the Company
EDSA
globenewswire.com31 October 2024

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD, Edesa's Chief Executive Officer and Founder, to invest up to $5.0 million in the company, including an immediate investment of approximately $1.5 million.

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
EDSA
globenewswire.com13 September 2024

MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), when combined with a series of transactions (the “Transactions”) that have occurred since the date of the most recent early warning report filed by Dr. Nijhawan on November 18, 2022 (the “Previous Report”), Dr. Nijhawan has acquired “beneficial ownership” of common shares in the capital of Edesa (“Common Shares”) in an amount equal to more than 2% of the issued and outstanding Common Shares since the date of the Previous Report.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
EDSA
globenewswire.com09 August 2024

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business.

Edesa Biotech to Participate in Barclays Global Healthcare Conference
Edesa Biotech to Participate in Barclays Global Healthcare Conference
Edesa Biotech to Participate in Barclays Global Healthcare Conference
EDSA
Accesswire07 March 2024

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management will participate in the Barclays 26th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024. Attendees interested in meeting with Edesa can request meetings through conference organizers or by contacting the company at [email protected].

FAQ

  • What is the primary business of Edesa Biotech?
  • What is the ticker symbol for Edesa Biotech?
  • Does Edesa Biotech pay dividends?
  • What sector is Edesa Biotech in?
  • What industry is Edesa Biotech in?
  • What country is Edesa Biotech based in?
  • When did Edesa Biotech go public?
  • Is Edesa Biotech in the S&P 500?
  • Is Edesa Biotech in the NASDAQ 100?
  • Is Edesa Biotech in the Dow Jones?
  • When was Edesa Biotech's last earnings report?
  • When does Edesa Biotech report earnings?
  • Should I buy Edesa Biotech stock now?

What is the primary business of Edesa Biotech?

EDSA Biotech focuses on developing innovative therapies for serious diseases. The company uses advanced technology to create treatments that target specific health issues. Their goal is to improve patient outcomes and contribute to the future of medicine through research and development in biotechnology.

What is the ticker symbol for Edesa Biotech?

The ticker symbol for Edesa Biotech is NASDAQ:EDSA

Does Edesa Biotech pay dividends?

No, Edesa Biotech does not pay dividends

What sector is Edesa Biotech in?

Edesa Biotech is in the Healthcare sector

What industry is Edesa Biotech in?

Edesa Biotech is in the Biotechnology industry

What country is Edesa Biotech based in?

Edesa Biotech is headquartered in Canada

When did Edesa Biotech go public?

Edesa Biotech's initial public offering (IPO) was on 21 June 2010

Is Edesa Biotech in the S&P 500?

No, Edesa Biotech is not included in the S&P 500 index

Is Edesa Biotech in the NASDAQ 100?

No, Edesa Biotech is not included in the NASDAQ 100 index

Is Edesa Biotech in the Dow Jones?

No, Edesa Biotech is not included in the Dow Jones index

When was Edesa Biotech's last earnings report?

Edesa Biotech's most recent earnings report was on 9 August 2024

When does Edesa Biotech report earnings?

The next expected earnings date for Edesa Biotech is 16 December 2024

Should I buy Edesa Biotech stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions